Combination of cyclic nucleotide modulators with P2Y12 receptor antagonists as anti‐platelet therapy
Open Access
- 11 April 2020
- journal article
- research article
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 18 (7) , 1705-1713
Abstract
No abstract availableKeywords
Funding Information
- British Heart Foundation (FS/16/1/31699, PG/15/47/31591, PG/15/79/31777, PG/17/40/33028)
- Fundação de Amparo à Pesquisa do Estado de São Paulo (14/04478‐5)
This publication has 33 references indexed in Scilit:
- Blockade of the purinergic P2Y 12 receptor greatly increases the platelet inhibitory actions of nitric oxideProceedings of the National Academy of Sciences, 2013
- Activation of Haem-Oxidized Soluble Guanylyl Cyclase with BAY 60-2770 in Human Platelets Lead to Overstimulation of the Cyclic GMP Signaling PathwayPLOS ONE, 2012
- Antiplatelet effects of aspirin vary with level of P2Y12 receptor blockade supplied by either ticagrelor or prasugrelJournal of Thrombosis and Haemostasis, 2011
- Anti‐platelet therapy: cyclo‐oxygenase inhibition and the use of aspirin with particular regard to dual anti‐platelet therapyBritish Journal of Clinical Pharmacology, 2011
- In the presence of strong P2Y12 receptor blockade, aspirin provides little additional inhibition of platelet aggregationJournal of Thrombosis and Haemostasis, 2010
- Dual antiplatelet therapy in cardiovascular disease: does aspirin increase clinical risk in the presence of potent P2Y12 receptor antagonists?: Figure 1Heart, 2010
- Recent developments in nitric oxide donor drugsBritish Journal of Pharmacology, 2007
- NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potentialNature Reviews Drug Discovery, 2006
- A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)The Lancet, 1996
- Platelet prostanoid receptorsPharmacology & Therapeutics, 1996